Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.

Gurudatta Naik; Sejong Bae; Mollie R. De Shazo; Pam Dixon; Lynn Merritt; A. Oliver Sartor; Frederick M. Schnell; Guru Sonpavde

doi:10.1200/jco.2018.36.6_suppl.224

Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.

Gurudatta Naik
, Sejong Bae
, Mollie R. De Shazo
, Pam Dixon
, Lynn Merritt
, A. Oliver Sartor
, Frederick M. Schnell
, Guru Sonpavde

Biostatistics, Data Science, & Epidemiology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Journal	Journal of Clinical Oncology
DOIs	https://doi.org/10.1200/jco.2018.36.6_suppl.224
State	Published - Feb 20 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1200/jco.2018.36.6_suppl.224

Cite this

@article{0bc0ce92db58437c8448bc5e4fec7ea4,

title = "Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.",

author = "Gurudatta Naik and Sejong Bae and Shazo, \{Mollie R. De\} and Pam Dixon and Lynn Merritt and Sartor, \{A. Oliver\} and Schnell, \{Frederick M.\} and Guru Sonpavde",

year = "2018",

month = feb,

day = "20",

doi = "10.1200/jco.2018.36.6\_suppl.224",

language = "English (US)",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.

AU - Naik, Gurudatta

AU - Bae, Sejong

AU - Shazo, Mollie R. De

AU - Dixon, Pam

AU - Merritt, Lynn

AU - Sartor, A. Oliver

AU - Schnell, Frederick M.

AU - Sonpavde, Guru

PY - 2018/2/20

Y1 - 2018/2/20

UR - https://app.dimensions.ai/details/publication/pub.1101229449

U2 - 10.1200/jco.2018.36.6_suppl.224

DO - 10.1200/jco.2018.36.6_suppl.224

M3 - Article

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.

UN SDGs

Access to Document

Other files and links

Cite this